Medication Review: Safety and Efficacy of Guselkumab in Crohn’s Disease and Ulcerative Colitis

In this video, Kimberly Orleck, PA-C, senior director of advanced practice providers at United Digestive and board member of GHAPP, provides a comprehensive review of the efficacy and safety data supporting guselkumab in the treatment of moderate to severely active ulcerative colitis and Crohn’s disease. Drawing from pivotal clinical trials, including QUASAR for ulcerative colitis and GALAXI and GRAVITY for Crohn’s disease, she walks through induction and maintenance dosing strategies, rapid onset of symptomatic improvement, and key clinical, endoscopic, and long-term remission outcomes. The discussion highlights early separation from placebo, durable remission through one and two years, and consistent efficacy in both biologic-naïve and biologic-experienced patients. Safety data across studies demonstrate a well-tolerated profile with adverse event rates comparable to placebo and no new safety signals identified. With both IV and subcutaneous induction options available for Crohn’s disease and flexible maintenance dosing for both indications, this overview places guselkumab within the evolving treatment landscape and current clinical guidelines for inflammatory bowel disease. For more information, please visit RhAPP.org, the Content Rheum or the RHAPP ACE 2.0 app.